Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

In-situ drug controlled release system for lesions and manufacturing method thereof

A technology of controlled release and drug application in the field of medical devices, which can solve the problems of limited drug loading and insufficient infiltration depth of lesion cells

Active Publication Date: 2020-02-28
SHENZHEN UNIV
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Aiming at the deficiencies of the prior art, the object of the present invention is to provide a lesion-in-situ drug controlled release system and a preparation method thereof, the lesion-in-situ drug controlled release system can greatly increase the drug loading and drug infiltration depth of the drug-loading system , to solve the problems of the limitation of drug loading in the current drug delivery system and the insufficient infiltration depth of the lesion cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • In-situ drug controlled release system for lesions and manufacturing method thereof
  • In-situ drug controlled release system for lesions and manufacturing method thereof
  • In-situ drug controlled release system for lesions and manufacturing method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0096] This embodiment provides a system for controlled drug release in situ at the lesion, which includes a 26G electrospinning needle, an inner polyethylene glycol (molecular weight 6000Da) coating covering the outer surface of the needle, and an outer coating covering the outer surface of the inner coating. Copolymer of polylactic acid-co-glycolic acid (molecular weight 60000Da) coating and a medical syringe connected with a needle.

[0097] Its preparation method is:

[0098] (1) Dissolve polylactic acid-glycolic acid copolymer and N,N-dimethylformamide under heating and stirring at 35°C, and the solution concentration is 80%; dissolve polyethylene glycol and ethanol at 35°C Heat and stir to dissolve, the solution concentration is 85%;

[0099] (2) Use a 26G electrospinning needle to dip the polyethylene glycol solution into glue at 25°C, and then vacuum-dry it at 25°C for 2 hours;

[0100] (3) The 26G spinning needle with the inner layer coating is dipped in the polylac...

Embodiment 2

[0107] This embodiment provides a system for controlled drug release in situ at the lesion, which includes a 26G electrospinning needle, an inner polyethylene glycol (molecular weight 6000Da) coating covering the outer surface of the needle, and an outer coating covering the outer surface of the inner coating. Copolymer of polylactic acid-co-glycolic acid (molecular weight 60000Da) coating and a medical syringe connected with a needle.

[0108] Its preparation method is consistent with embodiment 1.

[0109] Carry out drug release experiment to the obtained product, and draw release curve, method is as follows:

[0110] (1) Load the drug 5-fluorouracil in the hollow part of the product, and the mass of 5-fluorouracil is 50% of the total mass of the inner coating and the outer coating, and the upper and lower ends are capped with polylactic acid-glycolic acid copolymer, and then its Put it into a centrifuge tube containing 10 mL of fresh Tris-HCl solution;

[0111] (2) Then p...

Embodiment 3

[0115] This embodiment provides a system for controlled drug release in situ at the lesion, which includes a 26G electrospinning needle, an inner polyethylene glycol (molecular weight 6000Da) coating covering the outer surface of the needle, and an outer coating covering the outer surface of the inner coating. Copolymer of polylactic acid-co-glycolic acid (molecular weight 60000Da) coating and a medical syringe connected with a needle.

[0116] Its preparation method is consistent with embodiment 1.

[0117] Carry out drug release experiment to the obtained product, and draw release curve, method is as follows:

[0118] (1) The drug capecitabine is loaded into the hollow part of the product, the quality of capecitabine is 50% of the total mass of the inner coating and the outer coating, and the upper and lower ends are capped with polylactic acid-glycolic acid copolymer, and the latter Put it into a centrifuge tube containing 10 mL of fresh PBS solution;

[0119] (2) Then pu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
number average molecular weightaaaaaaaaaa
number average molecular weightaaaaaaaaaa
number average molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to an in-situ drug controlled release system for lesions and a manufacturing method thereof. The in-situ drug controlled release system for lesions comprises a drug injection needle, a polymer coating coating the outer surface of the drug injection needle and a drug propeller connected with the drug injection needle. The coating used in the drug controlled release system belongs to a biodegradable polymer material, which is safe and reliable, does not need to be taken out twice, and is biodegradable in vivo; the drug controlled release system has a hollow needle-like structure, and the drug loading can be greatly improved by the hollow empty cavity, so that the problem of insufficient drug loading in the current drug loading system is solved; and the system can be inserted into dense tissues inside the lesions and release therapeutic drugs from the inside, which greatly improves the depth of drug penetration in the implanted needle system and greatly improves thecure rate and reduces the recurrence.

Description

technical field [0001] The invention belongs to the technical field of medical devices, and in particular relates to a lesion in-situ drug controlled release system and a preparation method thereof. Background technique [0002] At present, in the treatment of tumors, for unresectable tumors (such as T4, M1-M2 types), even if high-dose radiotherapy and chemotherapy are used, the tumor treatment effect is very little. In the process of circulation, most of the drugs will be metabolized by the patient's liver, resulting in low concentration of drugs that can stay in the tumor in situ, low drug utilization, and poor inhibition and effect on tumor cells; If damage is caused, there will be a tumor stress response, leading to excessive proliferation and multiple metastasis of the tumor; third, radiotherapy and chemotherapy will cause serious secondary damage to the patient and aggravate the pain of the patient. [0003] Therefore, reducing systemic toxicity and improving the loca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61L31/10A61L31/14A61M5/32A61M5/158
CPCA61L31/10A61L31/148A61M5/32A61M5/158A61L2420/08A61L2420/02
Inventor 陈灏伍家恩许杉杉刘颖韩志超
Owner SHENZHEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products